Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
| Revenue (Most Recent Fiscal Year) | $460.16M |
| Net Income (Most Recent Fiscal Year) | $-175.54M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 4.72 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.02 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -38.78% |
| Net Margin (Trailing 12 Months) | -38.15% |
| Return on Equity (Trailing 12 Months) | -22.81% |
| Return on Assets (Trailing 12 Months) | -15.04% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.45 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.27 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2.98 |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.39 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.46 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.61 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 112.81M |
| Free Float | 107.22M |
| Market Capitalization | $2.17B |
| Average Volume (Last 20 Days) | 0.58M |
| Beta (Past 60 Months) | 0.85 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.96% |
| Percentage Held By Institutions (Latest 13F Reports) | 41.65% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |